Asghar Aghamohammadi

Asghar Aghamohammadi

Auto-generated profile, based on publicly available information

Asghar Aghamohammadi

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in The American Journal of Human Genetics
Verified
Journal Article
Open access
GLGabriela Lopez-Herrera
Gabriela Lopez-Herrera
GTGiacomo Tampella
Giacomo Tampella
QPQiang Pan-Hammarström
Qiang Pan-Hammarström
PHPeer Herholz
Peer Herholz
CTClaudia M. Trujillo-Vargas
Claudia M. Trujillo-Vargas
BGBodo Grimbacher
Bodo Grimbacher
Most autosomal genetic causes of childhood-onset hypogammaglobulinemia are currently not well understood. Most affected individuals are simplex cases, but both autosomal-dominant and autosomal-recessive inheritance have been described. We performed genetic linkage analysis in consanguineous families affected by hypogammaglobulinemia. Four consanguineous families with childhood-onset humoral immune deficiency and features of autoimmunity shared genotype evidence for a linkage interval on chromosome 4q. Sequencing of positional candidate genes revealed that in each family, affected individuals had a distinct homozygous mutation in LRBA (lipopolysaccharide responsive beige-like anchor protein). All LRBA mutations segregated with the disease because homozygous individuals showed hypogammaglobulinemia and autoimmunity, whereas heterozygous individuals were healthy. These mutations were absent in healthy controls. Individuals with homozygous LRBA mutations had no LRBA, had disturbed B cell development, defective in vitro B cell activation, plasmablast formation, and immunoglobulin secretion, and had low proliferative responses. We conclude that mutations in LRBA cause an immune deficiency characterized by defects in B cell activation and autophagy and by susceptibility to apoptosis, all of which are associated with a clinical phenotype of hypogammaglobulinemia and autoimmunity.

28 December 2015 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
OAOmar K. Alkhairy
Omar K. Alkhairy
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
NRNima Rezaei
Nima Rezaei
MFMingyan Fang
Mingyan Fang
KAKasper Krogh Andersen
Kasper Krogh Andersen
Lennart HammarströmLennart Hammarström
Lennart Hammarström

27 January 2017 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RYR. Yazdani
R. Yazdani
GAGholamreza Azizi
Gholamreza Azizi
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
AAA. Aghamohammadi
A. Aghamohammadi

6 August 2008 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
AAAsghar Aghamohammadi
Asghar Aghamohammadi
TCTaher Cheraghi
Taher Cheraghi
MGMohammad Gharagozlou
Mohammad Gharagozlou
MMMasoud Movahedi
Masoud Movahedi
NRNima Rezaei
Nima Rezaei
MMMostafa Moin
Mostafa Moin

16 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMaria Elena Maccari
Maria Elena Maccari
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
AAAsghar Aghamohammadi
Asghar Aghamohammadi
AAAlessandro Aiuti
Alessandro Aiuti
OAOlga Aleinikova
Olga Aleinikova
SEStephan Ehl
Stephan Ehl
Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2–3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.

27 January 2019 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
PAParisa Amirifar
Parisa Amirifar
MRMohammad Reza Ranjouri
Mohammad Reza Ranjouri
RYReza Yazdani
Reza Yazdani
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
AAAsghar Aghamohammadi
Asghar Aghamohammadi